Skip to main
LFMD

LifeMD (LFMD) Stock Forecast & Price Target

LifeMD (LFMD) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

LifeMD Inc. has demonstrated robust growth, with its Telehealth active subscriber base increasing by 14% year-over-year, reaching 310,818 subscribers by the end of the third quarter of 2025. The company's total revenue for the period was reported at $60.2 million, reflecting a 12.7% year-over-year growth, with Telehealth revenue specifically rising 17.4% to $47.3 million, underscoring its strong market position. Additionally, the launch of new offerings, including Novo's GLP-1s at competitive pricing, alongside a solid investment in telehealth infrastructure, positions LifeMD for continued expansion and increased demand for its products and services.

Bears say

LifeMD Inc. reported a revenue of $60.2 million for the latest quarter, which represented a 13% year-over-year growth but fell short of consensus estimates, revealing concerns about slowing revenue growth, particularly in the Telehealth segment. The company's adjusted EBITDA of $5.1 million also missed expectations, exacerbating worries about its profitability trajectory amid reduced marketing of compounded products and increased competition in the healthcare space. Additionally, it revised its full-year revenue guidance downward, highlighting pressures from competitors and raising potential risks related to patient acquisition, profitability, and market positioning.

LifeMD (LFMD) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LifeMD and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LifeMD (LFMD) Forecast

Analysts have given LifeMD (LFMD) a Buy based on their latest research and market trends.

According to 7 analysts, LifeMD (LFMD) has a Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LifeMD (LFMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.